Published in Sci Transl Med on June 19, 2013
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother (2014) 1.66
Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci U S A (2014) 1.44
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect (2014) 1.18
Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol (2014) 1.02
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Res (2014) 0.99
Membrane binding and bending in Ebola VP40 assembly and egress. Front Microbiol (2014) 0.95
Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus. Infect Dis Poverty (2014) 0.94
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Res (2015) 0.94
Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo. MBio (2015) 0.93
Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin Microbiol Rev (2015) 0.92
Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature (2016) 0.92
Open drug discovery for the Zika virus. F1000Res (2016) 0.91
Small molecules with antiviral activity against the Ebola virus. F1000Res (2015) 0.90
FDA approved drugs as potential Ebola treatments. F1000Res (2015) 0.87
A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Negl Trop Dis (2016) 0.87
Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. ACS Infect Dis (2014) 0.87
The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes. J Biol Chem (2014) 0.86
Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol. Nat Commun (2015) 0.86
Machine learning models identify molecules active against the Ebola virus in vitro. F1000Res (2015) 0.85
Development and application of reporter-expressing mononegaviruses: current challenges and perspectives. Antiviral Res (2014) 0.83
Ebola Virus Infection: Overview and Update on Prevention and Treatment. Infect Dis Ther (2015) 0.83
Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus. Infect Dis Poverty (2016) 0.83
Ebola virus entry into host cells: identifying therapeutic strategies. Curr Clin Microbiol Rep (2015) 0.82
Lack of effect of lamivudine on Ebola virus replication. Emerg Infect Dis (2015) 0.82
Inhibition of Polyamine Biosynthesis Is a Broad-Spectrum Strategy against RNA Viruses. J Virol (2016) 0.81
Screen of FDA-approved drug library identifies maprotiline, an antibiofilm and antivirulence compound with QseC sensor-kinase dependent activity in Francisella novicida. Virulence (2015) 0.80
Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications. Viruses (2016) 0.79
Novel Small Molecule Entry Inhibitors of Ebola Virus. J Infect Dis (2015) 0.78
Possible FDA-approved drugs to treat Ebola virus infection. Infect Dis Poverty (2015) 0.77
Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits Candida albicans and Staphylococcus aureus biofilm formation in vivo. Antimicrob Agents Chemother (2014) 0.77
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts. J Med Chem (2016) 0.77
Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus. PLoS One (2016) 0.76
Large-Scale Screening and Identification of Novel Ebola Virus and Marburg Virus Entry Inhibitors. Antimicrob Agents Chemother (2016) 0.76
Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection. Front Microbiol (2015) 0.76
Repurposing Toremifene for Treatment of Oral Bacterial Infections. Antimicrob Agents Chemother (2017) 0.76
Antiviral Screening of Multiple Compounds against Ebola Virus. Viruses (2016) 0.75
Sex Drives Dimorphic Immune Responses to Viral Infections. J Immunol (2017) 0.75
Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res (2016) 0.75
Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. Am J Physiol Lung Cell Mol Physiol (2015) 0.75
Therapeutics for postexposure treatment of Ebola virus infection. Future Virol (2015) 0.75
Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks. Antimicrob Agents Chemother (2015) 0.75
Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. Sci Rep (2017) 0.75
Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection. Antimicrob Agents Chemother (2016) 0.75
Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med (2016) 0.75
Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. Assay Drug Dev Technol (2015) 0.75
Ebola hemorrhagic fever: current outbreak and progress in finding a cure. Daru (2014) 0.75
Integrated Computational Approach for Virtual Hit Identification against Ebola Viral Proteins VP35 and VP40. Int J Mol Sci (2016) 0.75
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl Trop Dis (2017) 0.75
Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. Curr Ther Res Clin Exp (2017) 0.75
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A (1995) 18.16
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature (2011) 5.68
A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol (2002) 5.49
Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 4.92
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50
Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol (2006) 4.24
Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature (2011) 3.66
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem (2002) 2.76
Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog (2010) 2.60
Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog (2010) 2.60
Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis (2004) 2.25
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1999) 2.24
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
Rapid detection protocol for filoviruses. J Clin Virol (2004) 2.13
Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J (2012) 2.08
Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol (2007) 1.93
Dengue virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog (2010) 1.67
Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv (2008) 1.61
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med (2004) 1.52
Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology (1997) 1.50
Filoviruses: Interactions with the host cell. Cell Mol Life Sci (2008) 1.48
Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol (2011) 1.46
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril (1986) 1.26
Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet (2003) 1.23
Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis (2011) 1.23
Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction. Virology (2009) 1.16
Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation (1996) 1.16
Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A (2010) 1.14
A new player in the puzzle of filovirus entry. Nat Rev Microbiol (2012) 1.08
Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses (2012) 1.04
Filovirus entry: a novelty in the viral fusion world. Viruses (2012) 1.03
Characterization of fluorescent sterol binding to purified human NPC1. J Biol Chem (2008) 1.01
The future of the new selective estrogen receptor modulators. Menopause Int (2007) 0.99
Human umbilical vascular endothelial cells express estrogen receptor beta (ERbeta) and progesterone receptor A (PR-A), but not ERalpha and PR-B. Histochem Cell Biol (2008) 0.94
Estrogen receptors alpha and beta have similar activities in multiple endothelial cell pathways. Endocrinology (2002) 0.90
Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology (2003) 0.85
The Soviet Union's anti-agricultural biological weapons. Ann N Y Acad Sci (1999) 0.82
Clinical pharmacokinetics of toremifene. Clin Pharmacokinet (2000) 0.82
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol (2008) 5.26
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet (2010) 4.52
Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today (2006) 4.24
Effective post-exposure treatment of Ebola infection. PLoS Pathog (2007) 3.69
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio (2014) 3.49
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci U S A (2006) 3.25
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Comprehensive panel of real-time TaqMan polymerase chain reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World hantaviruses. Am J Trop Med Hyg (2010) 2.92
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A (2012) 2.83
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Molecular Evidence of Sexual Transmission of Ebola Virus. N Engl J Med (2015) 2.71
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis (2007) 2.68
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol (2008) 2.58
A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A (2010) 2.41
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol (2009) 2.41
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine (2008) 2.33
Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med (2013) 2.29
Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nat Struct Mol Biol (2012) 2.27
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol (2009) 2.15
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis (2007) 2.09
Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog (2006) 2.01
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol (2006) 1.85
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci U S A (2011) 1.80
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
The avian retrovirus avian sarcoma/leukosis virus subtype A reaches the lipid mixing stage of fusion at neutral pH. J Virol (2003) 1.63
Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein. J Virol (2004) 1.62
Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis (2011) 1.62
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med (2004) 1.52
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
Fusion peptide of influenza hemagglutinin requires a fixed angle boomerang structure for activity. J Biol Chem (2005) 1.51
Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. J Virol (2011) 1.46
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate. J Virol (2004) 1.44
In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. J Infect Dis (2007) 1.43
Postexposure treatment of Marburg virus infection. Emerg Infect Dis (2010) 1.43
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Integrin alpha5beta1 supports the migration of Xenopus cranial neural crest on fibronectin. Dev Biol (2003) 1.37
Comparative analysis of viral gene expression programs during poxvirus infection: a transcriptional map of the vaccinia and monkeypox genomes. PLoS One (2008) 1.37
Leash in the groove mechanism of membrane fusion. Nat Struct Biol (2003) 1.36
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis (2012) 1.32
Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J (2007) 1.30
Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection. PLoS One (2013) 1.29
Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report. Virol J (2011) 1.29
Mesendoderm extension and mantle closure in Xenopus laevis gastrulation: combined roles for integrin alpha(5)beta(1), fibronectin, and tissue geometry. Dev Biol (2002) 1.29
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
The pathogenesis of Rift Valley fever virus in the mouse model. Virology (2010) 1.28
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins. Proc Natl Acad Sci U S A (2009) 1.26
Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol (2005) 1.24
Evolution of ebola virus disease from exotic infection to global health priority, Liberia, mid-2014. Emerg Infect Dis (2015) 1.21
Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proc Natl Acad Sci U S A (2011) 1.20
Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell (2005) 1.20
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A (2010) 1.14
Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis (2007) 1.13
Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis (2007) 1.13
Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis (2007) 1.12
Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis (2011) 1.12
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol (2013) 1.11
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Knocking out multigene redundancies via cycles of sexual assortment and fluorescence selection. Nat Methods (2011) 1.08
Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med (2005) 1.08